The in-vivo assessment of cerebral amyloid load is taking a leading role in the early differential diagnosis of neurodegenerative diseases. With the hopefully near introduction of disease-modifying drugs, we expect a paradigm shift in the current diagnostic pathway with an unprecedented surge in the request of exams and detailed analysis.
From clinics to methods and back: a tale of amyloid-PET quantification
CHINCARINI, ANDREA
2018
Abstract
The in-vivo assessment of cerebral amyloid load is taking a leading role in the early differential diagnosis of neurodegenerative diseases. With the hopefully near introduction of disease-modifying drugs, we expect a paradigm shift in the current diagnostic pathway with an unprecedented surge in the request of exams and detailed analysis.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
phdunige_1412392.pdf
Open Access dal 23/11/2019
Dimensione
18.19 MB
Formato
Adobe PDF
|
18.19 MB | Adobe PDF | Visualizza/Apri |
I documenti in UNITESI sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento:
https://hdl.handle.net/20.500.14242/69791
Il codice NBN di questa tesi è
URN:NBN:IT:UNIGE-69791